1. Home
  2. LYRA vs BGMS Comparison

LYRA vs BGMS Comparison

Compare LYRA & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$1.32

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Logo Bio Green Med Solution Inc.

BGMS

Bio Green Med Solution Inc.

N/A

Current Price

$0.83

Market Cap

5.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LYRA
BGMS
Founded
2005
1996
Country
United States
Malaysia
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.0M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
LYRA
BGMS
Price
$1.32
$0.83
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$16.00
N/A
AVG Volume (30 Days)
64.2K
17.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,534,000.00
N/A
Revenue This Year
N/A
$137.21
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.08
$0.74
52 Week High
$37.50
$6.70

Technical Indicators

Market Signals
Indicator
LYRA
BGMS
Relative Strength Index (RSI) 40.29 36.87
Support Level $1.21 $0.74
Resistance Level $1.52 $1.12
Average True Range (ATR) 0.15 0.07
MACD 0.06 0.01
Stochastic Oscillator 72.12 54.96

Price Performance

Historical Comparison
LYRA
BGMS

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About BGMS Bio Green Med Solution Inc.

Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

Share on Social Networks: